摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4,4-dimethyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one | 56369-21-2

中文名称
——
中文别名
——
英文名称
4,4-dimethyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one
英文别名
4,4-dimethyl-1,3,4,5-tetrahydro-benzo[b][1,4]diazepin-2-one;4,4-dimethyl-1,3,4,5-tetrahydro-2H-1,5-benzodiazepin-2-one;4,4-dimethyl-4,5-dihydro-1H-benzo[b][1,4]diazepin-2(3H)-one;4,4-dimethyl-2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one;4,4-dimethyl-3,5-dihydro-1H-1,5-benzodiazepin-2-one
4,4-dimethyl-1,3,4,5-tetrahydro-2H-benzo[b][1,4]diazepin-2-one化学式
CAS
56369-21-2
化学式
C11H14N2O
mdl
MFCD21840720
分子量
190.245
InChiKey
LHMWSVAJMJMOSV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    253 °C(Solv: ethanol (64-17-5))
  • 沸点:
    362.0±31.0 °C(Predicted)
  • 密度:
    1.051±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    14
  • 可旋转键数:
    0
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.363
  • 拓扑面积:
    41.1
  • 氢给体数:
    2
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • 2,3,4,5-TETRAHYDRO-1H-1,5-BENZODIAZEPINE DERIVATIVE AND MEDICINAL COMPOSITION
    申请人:Wakamoto Pharmaceutical Co., Ltd.
    公开号:EP1820799A1
    公开(公告)日:2007-08-22
    The present invention has its object to provide a 2,3,4,5-tetrahydro-1H-1,5-benzodiazepine derivative represented with the Formula (1) , or the pharmaceutically acceptable salt, which is effective as a therapeutic and prophylactic agent for diabetes, diabetic nephropathy, or glomerulosclerosis.
    本发明的目的是提供一种用化学式(1)表示的2,3,4,5-四氢-1H-1,5-苯二氮䓬衍生物,或其药学上可接受的盐,作为治疗和预防糖尿病、糖尿病肾病或肾小球硬化的药剂。
  • Benzamide derivatives and pharmaceutical composition comprising the same
    申请人:Fujisawa Pharmaceutical Co., Ltd.
    公开号:US05521170A1
    公开(公告)日:1996-05-28
    Compounds having the structure below ##STR1## and pharmaceutically acceptable salts thereof exhibit vasopressin antagonistic activity, vasodilating activity, hypotensive activity, activity for inhibiting saccharide release in the liver, activity for inhibiting growth of mesagium cells, water diuretic activity, platelet agglutination inhibitory activity, oxytocin antagonistic activity and the like, and are useful in treating or preventing hypertension, heart failure, renal insufficiency, edema, ascites, vasopressin parasecretion syndrome, hepatocirrhosis, hyponatremia, hypokalemia, diabetic or circulation disorder, oxytocin related diseases and the like.
    具有以下结构的化合物##STR1##及其药学上可接受的盐具有抗利尿激素拮抗活性、扩张血管活性、降压活性、抑制肝脏糖分释放活性、抑制间质细胞生长活性、水利尿活性、抑制血小板凝聚活性、催产素拮抗活性等,可用于治疗或预防高血压、心力衰竭、肾功能不全、水肿、腹水、利尿激素分泌过多综合症、肝硬化、低钠血症、低钾血症、糖尿病或循环障碍、催产素相关疾病等。
  • BROMODOMAIN INHIBITORS AND USES THEREOF
    申请人:Albrecht Brian K.
    公开号:US20140135316A1
    公开(公告)日:2014-05-15
    The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    本发明涉及用作抑制含有溴域的蛋白质的化合物。本发明还提供了包含本发明化合物的药学上可接受的组合物,以及使用该组合物治疗各种疾病的方法。
  • Bromodomain inhibitors and uses thereof
    申请人:Albrecht Brian K.
    公开号:US09422292B2
    公开(公告)日:2016-08-23
    The present invention relates to compounds useful as inhibitors of bromodomain-containing proteins. The invention also provides pharmaceutically acceptable compositions comprising compounds of the present invention and methods of using said compositions in the treatment of various disorders.
    本发明涉及作为抑制溴域含蛋白的化合物。本发明还提供了包括本发明化合物的药学可接受的组合物,以及使用该组合物治疗各种疾病的方法。
  • Benzamide derivatives and their use as vasopressin antagonists
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0620216A1
    公开(公告)日:1994-10-19
    A compound of the formula : wherein R¹ ishydrogen or lower alkyl, R² ishydrogen, lower alkyl, halo(lower)alkyl, halogen or lower alkoxy, R³ and R⁴are each hydrogen, lower alkyl or taken together to form oxo, R⁵ ishydrogen, halogen, nitro, hydroxy, protected hydroxy, lower alkyl or lower alkoxy optionally substituted with lower alkylamino, R⁶ ishydrogen, lower alkyl or acyl, A is in which the substituents R⁷ to R¹³ and the symbol Y have certain meanings, and pharmaceutically accetable salts thereof, and processes for preparing them, and pharmaceutical compositions comprising them as an active ingredient.
    式中的化合物: 式中 R¹ 是氢或低级烷基、 R² 是氢、低级烷基、卤代(低级)烷基、卤素或低级烷氧基、 R³ 和 R⁴ 分别为氢、低级烷基或合在一起形成氧代、 R⁵ 是氢、卤素、硝基、羟基、受保护的羟基、低级烷基或可选择被低级烷基氨基取代的低级烷氧基、 R⁶ 是氢、低级烷基或酰基、 A 是 其中取代基 R⁷ 至 R¹³ 和符号 Y 具有特定含义,以及它们的可药用盐、它们的制备方法和包含它们作为活性成分的药物组合物。
查看更多